Melanoma accounts for 1.7% of global cancer diagnoses and is the fifth most common
cancer in the US. Melanoma incidence is rising in developed, predominantly fair-skinned …

Sinonasal malignancies make up< 5% of all head and neck neoplasms, with an incidence of
0.5–1.0 per 100,000. The outcome of these rare malignancies has been poor, whereas …

In less than 10 years, melanoma treatment has been revolutionized with the approval of
tyrosine kinase inhibitors and immune checkpoint inhibitors, which have been shown to …

Melanoma is the most aggressive and dangerous form of skin cancer that develops from
transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is …

The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …

Summary Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and
PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in …

In the past decade, major advances have been made in the understanding of melanoma.
New predisposition genes have been reported and key somatic events, such as BRAF …

Purpose Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas
provide therapeutic opportunities. Patients and Methods We conducted a multicenter phase …

Melanomas comprise multiple biologically distinct categories, which differ in cell of origin,
age of onset, clinical and histologic presentation, pattern of metastasis, ethnic distribution …

Context Some melanomas arising from acral, mucosal, and chronically sun-damaged sites
harbor activating mutations and amplification of the type III transmembrane receptor tyrosine …